The effects of intravenous isoproterenol upon the pressure-flow-volume relationships in the pulmonary vascular bed were studied in 34 patients and one normal subject during simultaneous right and transseptal left heart catheterization. In five patients with primary myocardial disease and in one normal subject, active pulmonary vasodilation was demonstrated by a significant increase in pulmonary blood volume (PBV) and a concomitant fall in pulmonary vascular distending pressure (PD). Infusion of the drug into 18 patients with mitral stenosis resulted in a concordant rise in PBV and PD, strongly suggesting passive distention of the pulmonary vascular bed. In contrast to the responses of these two groups of patients, isoproterenol infusion into 11 patients with aortic valve disease failed to change the PBV, but caused a significant decrease in PD.
and in patients with cardiopulmonary disease. [9] [10] [11] [12] [13] [14] [15] [16] Although the potent positive inotropic and chronotropic actions and the peripheral arterial vasodilatation effects of the drug have been consistently demonstrated, information regarding its effects upon the pulmonary circulation has been less well defined. Isoproterenol is considered a "pulmonary vascular vasodilator" because a fall in pulmonary vascular resistance is frequently observed after parenteral administration of the drug.4, 11, 17 However, other workersl'20 including ourselves2' have emphasized the necessity of measuring pulmonary blood volume (PBV), pulmonary vascular pressures, and left ventricular function in the assessment of pulmonary vasomotion. With the exception of a small series of patients who received sub-Circulation, Volume XXXVII, February 1968 lingual isoproterenol,22 no measurements of these variables have been made.
The following study was undertaken in order to define more clearly the cardiopulmonary effects of isoproterenol with particular reference to left ventricular function, to examine the mechanisms of alterations of the PBV after isoproterenol infusion, and to demonstrate the presence of both "active" and "passive" changes in the pulmonary circulation.
Methods
Forty-one patients (25 men and 16 women) between the ages of 27 and 61 years were studied. One patient (F.S.) was studied twice. The predominant lesion and the degree of functional impairment were determined on the basis of clinical examination, electrocardiograms, phonocardiograms, chest fluoroscopy and roentgenograms, simultaneous right and transseptal left heart catheterization, and selective angiocardiograms. In 24 patients with valvular heart disease the lesion was also confirmed at operation or postmortem examination.
Thirty-four patients received intravenous isoproterenol, while eight received a sham infusion of an equal volume of physiological saline.
Group I-sham infusion: Eight patients were investigated during a control period and after a 20-minute period of sham infusion. Four of these patients had mitral stenosis, two had aortic stenosis, one both mitral and aortic stenosis, and one mixed aortic stenosis and incompetence. In one patient (F.S.), data were obtained during both sham and isoproterenol infusions. In this group, patients O.F. and F.S. were considered to be severely incapacitated (class III-IV).
The patients who received isoproterenol infusions were divided into the following groups:
Group II-primary myocardial disease: Five patients were included in this group. The average age was 46 years. Each patient had evidence of cardiac enlargement of unknown etiology. Two of the patients (J.H. and V.R.) had a long-standing history of alcoholism.
Group III-mitral stenosis: In this group there were 18 patients whose average age was 41 years. In 17 patients the calculated mitral valve area was 1.2 cm2 or less. The entire group was arbitrarily divided into two subgroups on the basis of whether or not the pulmonary vascular Circulation, Volume XXXVII, February 1968 distending pressure (PD*) was increased by more than 1.5 mm Hg during isoproterenol infusion.
Subgroup lIlA consisted of six patients in whom PD increase did not exceed 1.5 mm Hg, and Subgroup IIIB consisted of 12 patients in whom PD increased by more than 1.5 mm Hg.
Group IV-aortic valvular disease: Eleven patients whose average age was 49 years were included in this group. In five of the patients severe aortic stenosis was present, while in two patients mixed aortic stenosis and incompetence was demonstrated. The remaining four patients had predominant aortic incompetence. Ten patients were well compensated, and one patient (F.S.) was in borderline congestive heart failure.
Right and transseptal left heart catheterization were performed in the manner described previously in detail.23 In 27 instances the left ventricular pressure was recorded at both high and low levels of gain during the control period. In 12 instances left ventricular pressure was measured during both the control and the infusion period. In the absence of mitral stenosis, the left atrial mean pressure was taken as an approximation of mean left ventricular filling pressure.
With cardiac catheters positioned in the main pulmonary artery and mid left atrium, respectively, indicator-dilution curves were recorded from a systemic artery after rapid successive injections of indocyanine green into each catheter, as previously described.23 Each curve was transcribed electronically onto IBM data cards that were fed into a previously programmed IBM Model 1620 computer for the determination of cardiac output and of mean transit time. The details of the computer program and analysis have been reported in recent communications from this laboratory.24 25 The "central" blood volume (CBV) is that volume between the main pulmonary artery and a systemic artery, including all temporally equidistant branches. The PBV is that volume within the pulmonary arteries, pulmonary capillaries, pulmonary veins, and an indeterminant portion of the left atrium. These volumes were calculated by the Stewart-Hamilton method26 as follows: Key to abbreviations: BSA=body surface area in m2; FC-functional classification according to New York State Heart Association; Dx = diagnosis; AS = aortic stenosis; AIaortic incompetence; MS = mitral stenosis; C = control period; S = sham infusion; NSR = normal sinus rhythm; AF = atrial fibrillation; CI = cardiac index (L/min/m2 BSA); HR = heart rate (beats/min); SI = stroke index (mi/beat/M2 BSA); PAm = pulmonary artery mean pressure; LAm = left atrial mean pressure; PD = pulmonary vascular distending pressure; LVD = left ventricular diastolic pressure; SAm = systemic artery mean pressure; Tm =mean transit time; PA-SA = puhnonary artery to systemic artery; PA-LA = pulmonary artery to left atrium; CBV= central blood volume; PBV = pulmonary blood volume; PVR = pulmonary vascular resistance; TSR = total systemic resistance. Where CBV = central volume (mI/Mr2) PBV = pulmonary blood volume (mI/M2) CI = mean cardiac index (ml/m2/sec) derived from the average of both curves TM(PA-SA) =-mean transit time in seconds from the pulmonary artery to a systemic artery TM (LA -SA) = mean transit time in seconds from the left atrium to a systemic artery TM (PA-SA) -T) M (LA-SA) = mean transit time from PA to LA. During a control period, PA, LA, and SA pressures, cardiac output, and the electrocardiogram were recorded. In 31 patients the PBV was determined in duplicate. In each of the remaining 10 patients, a single measurement of PBV was made. In previous work reported from this laboratory, the standard deviation for duplicate determinations of PBV in a given patient was 14.9 mi/M2.21
Following the control observations, isoproterenol in a concentration of 1.5 or 2.0 ,ug/ml in physiological saline was infused intravenously in 34 patients. A constant infusion rate ranging from 0.015 to 0.027 ,g/kg/min was maintained by a Harvard infusion pump. The volume infused did not exceed 20 ml in any instance. The pressures and heart rate were constantly monitored during the infusion. When a new steady state had been achieved as evidenced by composure of the patient and by constancy of change in pressures and heart rate, measurements of cardiac output and PBV, usually in duplicate, were repeated. The interval between the observations during the control period and those during the intervention varied from 12 to 20 minutes.
Results
The hemodynamic data for each group of patients are summarized in tables 1 the changes resulting from the sham or isoproterenol infusions are compared in table 5 . Group I-sham infusion (tables 1 and 5): In this group of patients the mean heart rate, cardiac index (cardiac output/M2 BSA), and stroke index (stroke volume/M2 BSA) were virtually unchanged during the period of observation. Although PAm pressure decreased in five of the eight patients, the changes were insignificant. The LAm pressure averaged 19 mm Hg during the control period and did not change during the sham infusion. Practically no change in PD pressure (from 26.4 to 25.6 mm Hg) was observed. The PBV averaged 286 ml/m2 during the control period and 289 ml/m2 during the sham infusion. Values for CBV changed little during the two periods of observation, and no significant changes were detected in pulmonary vascular resistance (PVR) or in total systemic resistance (TSR).
Group II-primary myocardial disease (tables 2 and 5): In contrast to the sham infusion group, the average heart rate, cardiac index, and stroke index increased significantly.
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These sistent changes were associated with a condecrease in PAm, LAm, and PD pressures in each patient. In four of the five patients SAm pressure also decreased. The LVD pressure decreased in each of the two patients in whom the measurement was made during both periods of observation. Statistically significant falls in pressure were noted only in the average LAm and average SAm pressures. Significant changes in the other pressures were obscured by the large decreases in PAm and PD in patient J.H. This patient was the only one in this group who had significant elevations of PAm, LAm, PD and LVD pressure during the control period. In the entire group PBV and CBV rose significantly by 39 Ml/m2 and 86 Ml/m2, respectively. The PVR was not altered significantly, although the TSR fell from 1995 to 1177 dynes sec/cm5. Group III-mitral stenosis (tables 3 and 5): In these patients the average heart rate increased from 76 to 98 beats per minute, and the average cardiac index increased from There was a significant increase in both PBV and CBV, the former by 62 ml/m2 and the latter by 62 m/m2. A substantial decrease in PVR was observed in this group. As mentioned previously, in an effort to delineate the relationship between the rise in pulmonary vascular pressures and that in PBV, the group was further divided into two subgroups.
Subgroup IIIA: Among the six patients of this subgroup, although the increments in heart rate and cardiac index were nearly identical to the values observed in the entire group, the PD increased by only 1.5 mm Hg or less. The average SAm pressure decreased by 11 mm Hg. The LVD pressure fell 3 to 8 mm Hg in four patients in whom it was measured. Pulmonary blood volume increased by 42 ml/m2, whereas the CBV rose by 31 ml/m2. No significant change occurred in the PVR, although the TSR decreased 594 dynes sec/cm5. Subgroup IIIB: The positive chronotropic and inotropic effects of isoproterenol were of similar magnitude to those in subgroup IIIA. The average PAm, LAm, and PD pressures increased 7.5, 6.6, and 7.1 mm Hg, respectively. There was a significant decrease in PVR. The average increase in PBV was 66 mI/M2, and the average increase in CBV was 80 ml/m2. Thus, the increase in PBV in this subgroup was approximately one and onehalf times that observed in subgroup IIIA.
Group IV-aortic valvular disease (tables 4 and 5): In this group of patients, the heart rate, cardiac index, and stroke index each increased significantly. An increase in stroke index was observed both in patients with predominant aortic stenosis and in those with predominant aortic incompetence. Although the average PAm pressure was not changed, significant decreases were noted in the average LAm, PD, and SAm pressures. Although the changes in CBV were not significant, there If the data from patient F.S. were excluded, a significant decrease in average PAm, LAm, and PD was observed in this group. Despite these changes in cardiovascular pressures, the PBV and CBV were unaltered. Of further significance was the observation that PVR did not change although there was a marked fall in TSR.
Discussion
During the sham infusion studies four of the eight patients were also observed during a 15to 20-minute "recovery" period following the infusion. When these data were compared with those obtained during either control or the sham infusion period, no significant differences were found in any parameter. Thus, it would appear that a steady state can be maintained with reasonable assurance in most patients for periods of 30 to 40 minutes or longer.
In the five group II patients isoproterenol caused a fall in the average PAm, LAm, PD, and SAm pressures. Similar findings were also observed during isoproterenol infusion in another patient with normal hemodynamics (fig. 1 ). The LVD pressure decreased in each of the three patients in whom the measurement was made. In the remaining three patients a fall in LAm pressure must have reflected a decrease in LVD, since mitral valve lesions were absent in all six patients. Despite a fall in these pressures, increases in PBV and CBV were observed. This discordant change in pulmonary vascular pressures and volumes is consistent with active pulmonary vasodilation associated with a positive inotropic effect upon the heart. However, no appreciable change in PVR occurred. The directional changes in average PAm, LAm, PD, and PBV are in general agreement with the report of McGaff and associates,22 who studied seven patients before and after sublingual administration of 10 to 20 mg of isoproterenol.
Our findings also are in accord with the results obtained in dogs in which pulmonary vasodilation following isoproterenol was demonstrated in vivo,27-29 in vitro,30 and in isolated perfused lung preparations. 3' In contrast to the patients with primary Circulation, Volume XXXVII, February 1968 myocardial disease, patients with mitral stenosis (group III) exhibited a concordant rise in both PBV and PD. These findings suggest a predominant passive distention of the pulmonary vascular bed secondary to an increase in intravascular pressures following an augmentation in cardiac output in the presence of mitral valve obstruction. It is likely that the effect of any active pulmonary vasodilation in this group was at least partially masked by the predominant passive distention of the pulmonary vascular bed. Our findings verify the supposition of Whalen and associates,13 who suggested that the PBV might increase in patients with mitral stenosis in response to parenteral isoproterenol. That the magnitude of increase in both LAm and PAm pressures is of importance in determining the PBV is suggested by the comparison of the PBV response in patients of group IIIA with that of group IIIB. In the latter group of Comparison of Hemodynamic Changes Resulting from Sham isoproterenol is characterized by a significant increase in cardiac index (CI), a fall in pulmonary vascular pressures (PAm and LAm), and a significant increase in pulmonary blood volume (PBV). Note that the total systemic resistance (TSR) fell, whereas there was no change in the pulmonary vascular resistance (PVR). patients in whom there was a greater increase in PD pressure, an additional average icrease of 24 mI/M2 in PBV and of 49 ml/M2 in CBV was found.
The response of the PBV and CBV in group IV patients with aortic valve lesions to isoproterenol differed from that observed in either group II or group III patients. The change in either PBV or CBV was insignificant despite a decrease in the average PAm, LAm, and PD in 10 of the 11 patients. The magnitude of the reduction in the average LAm pressure in patients with aortic valve disease was almost identical to that observed in patients with primary myocardial disease, although the decrease in the average PAm pressure was slightly greater in the latter group of patients. The reduction in pulmonary vascular pressures associated with but minor changes in PBV in group IV patients may be the result of the interaction of multiple fac- been more convincingly demonstrated in man by studies by using epicardial clips attached to the ventricles at the time of corrective cardiac surgery.14 In addition, others employing the thermodilution technique have noted decreases in left ventricular end-diastolic end end-systolic volumes during isoproterenol infusions in patients with normal left ventricular volumes16 and in patients with aortic incompetence.32 It would seem reasonable to infer that these volume changes would also tend to reduce the PBV. Similar studies in patients with severe aortic stenosis and increased resting left ventricular end-diastolic volumes have indicated that left ventricular end-diastolic, end-systolic volumes, and left ventricular diastolic pressure frequently increased to some degree during drug administration."6 On the other hand, in patients with aortic stenosis in whom the resting left ventricular end-diastolic volumes were normal, or occasionally when elevated, the same workers noted that isoproterenol caused a reduction in these volumes as well as in LVD.
Extrapolation of these findings to the present investigation suggest that the PBV might decrease, remain unchanged, or increase in response to isoproterenol, depending upon the severity of the aortic valve obstruction and the magnitude of the resting left ventricular end-diastolic volumes in our patients. For example, in four of the five patients with severe aortic stenosis, the LAm pressure fell significantly as did the LVD pressure when measured. One may speculate that both the left ventricular end-diastolic and end-systolic volumes probably would have decreased in these patients. This reduction in left ventricular volume in turn would tend to diminish the PBV, if no other factors were influencing the latter volume. On the other hand, in the fifth patient (F.S.), isoproterenol caused an increase in LAm and LVD pressures and probably in left ventricular end-diastolic and end-systolic volumes as well. Presumably these changes would tend to augment the PBV, an assumption confirmed by the observation that the PBV increased 55 ml/m2 in this patient.
If the positive inotropic action on the ventricle is the sole effect of isoproterenol in the central circulation, the mechanism of this action must be different from that of digitalis.
A previous report from this laboratory,33 more recently extended to observations in 23 patients,34 indicated that acute digitalization re-sults in a decrease in both PBV and CBV in patients in whom there is a concomitant fall in LVD, LAm, and PAm pressures. These changes are strongly suggestive of improvement in left ventricular performance resulting in a concordant fall in both pulmonary vascular pressures and PBV, which is clearly a passive effect.
If the positive inotropic effects of isoproterenol and digitalis were similar, and if the former drug had no other effects, then a decrease in LVD and PD noted in our patients should have been accompanied by a fall in PBV and CBV. However, each of the 17 patients exhibited an increase or no change in PBV and CBV. These findings might be accounted for by simultaneous active pulmonary vasodilation and a positive inotropic effect, the degree of expression of each factor being modulated by the underlying cardiopulmonary pathology.
As suggested by Rodbard,35 changes in bronchomotor tone and intra-alveolar pressure may have a considerable influence upon pulmonary artery pressure. Since isoproterenol is a powerful bronchodilator, its use may result in a decrease in intra-alveolar pressures, which in turn might induce a fall in pulmonary artery pressure due to mechanical effects of the bronchi upon the pulmonary arterial tree. This fall in pressure accompanied by a fall in LAm pressure due to the positive inotropic action of the drug may be partly responsible for the reduction in PD observed in patients of group II and group IV. However, increase in PBV in group II patients could not be due solely to this mechanism.
Since we did not document the bronchodilator action of isoproterenol in the present study, the relation of the change in PBV to that in bronchomotor tone remains uncertain.
